Expert view: Why you should use 3D models for high-throughput drug development screens
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.